Clinical Trial Update: Evaluation of a Therapeutic Strategy Including Nebulised Liposomal Amphotericin B (Ambisome®) in Maintenance Treatment of Allergic Bronchopulmonary Aspergillosis (Cystic Fibrosis Excluded). [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating nebulised liposomal amphotericin B (Ambisome) as maintenance therapy for Allergic Bronchopulmonary Aspergillosis in cystic fibrosis-exc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Bronchopulmonary Aspergillosis

Drugs mentioned

• AMBISOME (AMPHOTERICIN B)

Snippet

Sponsor: Poitiers University Hospital | Conditions: Allergic Bronchopulmonary Aspergillosis | Phase 2 | Status: COMPLETED